Systemic sclerosis
Christopher P. Denton, Dinesh Khanna · The Lancet · 2017
Cited by 2,212 works. doi:10.1016/s0140-6736(17)30933-9
Authors
References
- 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Cyclophosphamide versus Placebo in Scleroderma Lung Disease
- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
- Interstitial Lung Disease in Systemic Sclerosis
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
- Selexipag for the Treatment of Pulmonary Arterial Hypertension
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- Update of EULAR recommendations for the treatment of systemic sclerosis